Biologic activity of polyethylene Glycol12000-interferon-α2b compared with interferon-α2b:: Gene modulatory and antigrowth effects in tumor cells

被引:12
作者
Vyas, K
Brassard, DL
Delorenzo, MM
Sun, YP
Grace, MJ
Borden, EC
Leaman, DW
机构
[1] Univ Toledo, Dept Biol Sci, Toledo, OH 43606 USA
[2] Cleveland Clin, Taussig Canc Ctr, Cleveland, OH 44106 USA
[3] Lerner Res Inst, Cleveland, OH USA
[4] Schering Plough Res Inst, Union, NJ USA
来源
JOURNAL OF IMMUNOTHERAPY | 2003年 / 26卷 / 03期
关键词
apoptosis; interferon-stimulated genes; proliferation; signal transducer and activator of transcription; complexes;
D O I
10.1097/00002371-200305000-00004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The relative activities of interferon-alpha2b (IFN-alpha2b) and polyethylene glyCol(12000)-IFN-alpha2b (PEG-IFN-alpha2b) were assessed in cell culture studies using WM9 melanoma or ACHN renal cell carcinoma cell lines. Interferon-alpha2b and PEG-IFN-alpha2b had identical antiproliferative activities when tested in cell proliferation studies conducted with equivalent antiviral units of each IFN preparation. Neither IFN formulation was effective in inducing apoptosis in WM9 melanoma cells, but both increased slightly the percentage of ACHN cells undergoing apoptosis as assessed by Annexin V staining. Interferon-alpha2b and PEG-IFN-alpha2b both activated signal transducer and activator of transcription complexes, and the duration of complex activation was similar for both IFN formulations. Induction of different IFN-stimulated genes was assessed by Northern blotting and the quantitative real-time reverse transcription-coupled polymerase chain reaction (RT-PCR) in WM9 melanoma, ACHN renal cell carcinoma, U937 lymphoma, and MOLT-4 and Mono, Mac 6 leukemia cell lines. Interferon-alpha2b and PEG-IFN-alpha2b had equivalent gene-modulatory activities within each of these tumor cell lines, although cell line-spepific induction patterns were observed. When Compared with the antiviral 50% inhibitory concentration (IC50) values, the dose-dependent gene expression data correlated with cell sensitivity to IFN treatment. Together, the I drug comparability and cell sensitivity data suggest a predictive relation between dose, time, antiviral activity, and gene transcription effects. Therefore, although the specific activity of IFN-alpha2b is approximately three times greater than PEG-IFN-alpha2b, the two preparations have identical in vitro biologic activities when applied to cells at equivalent antiviral units.
引用
收藏
页码:202 / 211
页数:10
相关论文
共 21 条
[1]   Rational design of a potent, long-lasting form of interferon:: A 40 kDa branched polyethylene glycol-conjugated interferon α-2a for the treatment of hepatitis C [J].
Bailon, P ;
Palleroni, A ;
Schaffer, CA ;
Spence, CL ;
Fung, WJ ;
Porter, JE ;
Ehrlich, GK ;
Pan, W ;
Xu, ZX ;
Modi, MW ;
Farid, A ;
Berthold, W .
BIOCONJUGATE CHEMISTRY, 2001, 12 (02) :195-202
[2]  
Borden EC, 1998, SEMIN ONCOL, V25, P3
[3]  
BORDEN EC, 2000, CANC MED, P815
[4]  
Chawla-Sarkar M, 2001, CLIN CANCER RES, V7, P1821
[5]  
GAO PQ, 1993, J BIOL CHEM, V268, P12380
[6]   A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C [J].
Glue, P ;
Rouzier-Panis, R ;
Raffanel, C ;
Sabo, R ;
Gupta, SK ;
Salfi, M ;
Jacobs, S ;
Clement, RP .
HEPATOLOGY, 2000, 32 (03) :647-653
[7]   Structural and biologic characterization of pegylated recombinant IFN-α2b [J].
Grace, M ;
Youngster, S ;
Gitlin, G ;
Sydor, W ;
Xie, L ;
Westreich, L ;
Jacobs, S ;
Brassard, D ;
Bausch, J ;
Bordens, R .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2001, 21 (12) :1103-1115
[8]   Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis C [J].
Jen, JF ;
Glue, P ;
Ezzet, F ;
Chung, C ;
Gupta, SK ;
Jacobs, S ;
Hajian, G .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (06) :407-421
[9]  
KIRKWOOD J, 1993, P AN M AM SOC CLIN, V12, P390
[10]   INTERFERON-ALFA AND VINBLASTINE VERSUS MEDROXYPROGESTERONE ACETATE IN THE TREATMENT OF METASTATIC RENAL-CELL CARCINOMA [J].
KRIEGMAIR, M ;
OBERNEDER, R ;
HOFSTETTER, A .
UROLOGY, 1995, 45 (05) :758-762